Clicky

Medite Cancer Diagnostics Inc(MDIT)

Description: Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.


Keywords: Biotechnology Life Sciences Biology Medical Technology Biomarkers Anatomical Pathology Histology Staining

Home Page: medite-group.com

10524 Moss Park Road
Orlando, FL 32832
United States
Phone: 407-996-9630


Officers

Name Title
Mr. Jeffrey Rencher Chief Marketing & Bus. Devel. Officer
Ms. Susan Weisman Consultant

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2114
Price-to-Sales TTM: 0.1056
IPO Date:
Fiscal Year End: December
Full Time Employees: 69
Back to stocks